Diabetes Technology & Therapeutics
Information For Authors
Submitting Your Manuscript
ORCID IDs
The submitting author is required to complete the submission using an ORCID identifier. Please visit the ORCID website for more information, or to register. You must have an account in ScholarOne for Diabetes Technology & Therapeutics before logging in with an ORCID identifier.
Manuscript Submission Site
Create an Account in ScholarOne
If you do not already have an account in ScholarOne for Diabetes Technology & Therapeutics, you will need to create one. Once you create your account, you may log in to the system to begin your submission. Each listed author on a submission must either have an account, or have one created, in the submission system.
Use of English Language
All submissions must be in English. Appropriate use of English is a requirement for review and publication in Diabetes Technology & Therapeutics. To support non-native speakers, Mary Ann Liebert, Inc., has partnered with Editage to provide language editing and translation services for a fee prior to official submission. To learn more about the services, please visit the Liebert Author Services website. Please note that employing the use of such services is not mandatory and using it, or any other language editing service, does not guarantee the acceptance of any paper. All submissions are subject to peer review.
CLICK HERE TO SUBMIT YOUR MANUSCRIPT
See JOURNAL STANDARDS AND BEST PRACTICES STATEMENT
Check the Journal’s PEER REVIEW POLICIES
Manuscript Preparation
Determining Authorship
(See AUTHORSHIP DEFINITION AND RESPONSIBILITIES)
All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a manuscript assumes responsibility and accountability for the results.
Submission Process
NOTE: Effective October 1, 2020, page charges of $75.00 per typeset page will be implemented on all accepted manuscripts.
CLICK HERE FOR ARTICLE TYPES AND WORD LIMITS
All Original submissions must contain:
An Institutional Review Board (IRB) approval (or waiver) statement in the Methods section
Acknowledgments section (if applicable) after the Conclusion of the manuscript, followed by
An Author Contribution statement for each listed author, followed by
An Author Disclosure Statement for each author listed on a submission, even if there are no conflicts to disclose, followed by,
Funding statement(s), even if there is no funding information to declare.
See IRB APPROVALS, PATIENT CONSENT, & ETHICAL TREATMENT OF ANIMALS
See AUTHOR CONFIRMATION AND DISCLOSURE STATEMENTS
See FUNDING INFORMATION: COMPLIANCE AND STATEMENTS
Note: Just Accepted / Instant Online Publication
Diabetes Technology & Therapeutics publishes all accepted papers within 72 hours of receipt of all authors' signed copyright agreement forms in their unedited, uncorrected format.
It is important to note that the information that is published online, and in all indexing services, is pulled directly from the data that are populated into the fields in ScholarOne – NOT from the manuscript file – when the paper is originally uploaded to the system for peer review. Consequently, any errors contained in the system will remain on our website and all indexing services, including Medline, until the next revision* of the article is published. As such, it is critical that authors enter all authors’ names correctly into the system at the time of submission. Any omissions or errors will remain on our website and in indexing services until the subsequent online version is published.
*The next revision will take place after the corresponding author reviews page proofs, makes any necessary corrections, and returns the changes to the Publisher. Once the alterations are completed, the revised version will be published on our website, and the newly corrected information will then be released to Medline/PubMed, in addition to any other indexing services in which the Journal is included.
Please note that the typical time between acceptance of a paper and page proof distribution is approximately 4 (four) weeks depending on the length and complexity of the paper.
Supplemental Information, if supplied, will NOT be published in the Just Accepted/LION platform, but instead will be published in the Online Now (epub) and final versions of the article. Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)
All manuscripts must be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
When submitting your manuscript for peer review, be prepared to:
Enter the full title of the manuscript
Enter the full names and institutional affiliations of ALL listed author
Enter ALL listed authors' institutional email addresses
Identify the corresponding author
Enter a running (abbreviated) title of no more than 45 characters (including spaces).
Enter 3–6 keywords or phrases.
Provide a structured abstract of no more than 250 words, stating the background, materials and methods, results, and conclusions drawn from the study.
Provide the names and email addresses of at least five potential preferred reviewers familiar with the field.
Please make sure preferred reviewers are not from your university or institution or with whom you have collaborated.
Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer.
Ultimate reviewer selection is at the Editor’s discretion.
Confirm that the material has not been published or submitted for publication elsewhere.
Create an Effective Title
Manuscript titles should be brief, contain key terms, and clearly identify the purpose of the work conducted
Manuscript titles should not exceed 15 -18 words. Exceptions can be made with the Editor’s approval
Manuscript titles should be direct and to the point. Remember that the journal has a global readership, so clear and concise non-vernacular language is most effective
Avoid the use of specific locations in the title
Do not use proprietary/trademarked names in the title
Do not use acronyms in the title unless they are universally recognized and accepted
NOTE: The title page of your submission must be included as part of your main text document (not as a separate file).
File Naming
All file names should be in English and contain only alphanumeric characters. Do not include spaces, symbols, special characters, dashes, dots, or underscores. Label each file with the first author's last name, followed by the content of the file (i.e.: SmithText; SmithTables; SmithFigureLegends; SmithFig1, etc.)
Important: Please upload individual files of all manuscript material as described herein — please do NOT upload a combined PDF file containing all material in your submission.
Preparation of Manuscript
Prepare text of manuscripts, figure legends, and tables in Microsoft Word, double spaced. The order of elements in each manuscript should be:
Title page (with full manuscript title, all contributing authors and their affiliations, a short running title, a denotation of the corresponding author, and a list of 3-6 keywords)
Abstract
Main text (do not embed figures or tables)
Conclusion (as a separate paragraph, not as part of the Discussion section)
Acknowledgments (if applicable)
Authorship confirmation statement (see below)
Author(s’) disclosure statement(s) (see below)
Funding statement (see below)
References
Figure legends
Tables
Supplemental files (if applicable. If the submission is accepted, Supplemental Information will NOT be published in the Just Accepted/LION platform, but instead will be published in the Online Now (epub) and final versions of the article. Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)
Manuscript Text
Maximum word count for original articles should not exceed 5,000 words. In general, the text should be organized under the headings: Introduction, Materials and Methods, Results, Discussion, and Conclusions. Use only standard abbreviations, which can be found in the AMA’s Manual of Style for Authors & Editors or the Council of Biology Editors Style Manual, 10/e. At first usage, spell out terms and provide abbreviations in parentheses. Thereafter, use only the abbreviations. It is not necessary to spell out standard units of measure. Use generic names for drugs if possible. If you wish to use a proprietary drug name the first time it appears, use the generic name followed by the proprietary name, manufacturer, and location in parentheses.
References
References must be prepared in word, double spaced, and numbered consecutively as they are cited in the text (using superscript numbers). Include the reference section as part of the main text file, not as a separate file. References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by PubMed/Medline. List the first three authors followed by et al. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (AB Jones, personal communication). Include among the references any articles that have been accepted but have not yet published; identify the name of publication and add "In Press." If the reference has been published online, provide the DOI number in place of the page range.
Sample style for references:
Journal article:
Bergenstal RM, Mark Peyrot M, Dreon DM, et al.: Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther 2019;21:273-285.
Book:
Holt RIG, Cockram CS, Flyvbjerg A, et al., eds.: Textbook of Diabetes, Fifth Edition. Chichester, UK: John Wiley & Sons, Ltd., 2017.
Chapter in a book:
Horwitz DL, Klonoff DC: New technologies for glucose monitoring and insulin administration. In: Holt RIG, Cockram CS, Flyvbjerg A, et al., eds. Textbook of Diabetes, Fifth Edition. Chichester, UK: John Wiley & Sons, Ltd., 2017; pp. 414-425.
Figure Legends
Figure legends should be uploaded as a separate Word file and double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. that appear in the figure. If the illustration is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.
Tables
All tables should be prepared in one single Word file. Provide a title for each table. Cite tables in sequence in the text. Explain abbreviations used in the body of the table in footnotes. Details of experimental conditions should be included in the table footnotes. If the table is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.
Figures
Submission of high resolution .TIFF or .EPS figure files is strongly recommended.
Figures should not be embedded within the manuscript file.
Cite figures consecutively in text within parentheses.
A legend should be supplied for each figure and all legends numbered consecutively.
Images should not show the name of a patient or a manufacturer.
Do not include any illustrations as part of your text file.
When displaying glucose levels on the vertical axis, one may use units of mg/dL on the left-hand axis, and mmol/L on the right-hand axis, or vice versa, when feasible. Similarly, when displaying HbA1c values, it is desirable to display the National Glycohemoglobin Standardization Program (NGSP) “%” values on the left-hand axis and the International Federation of Clinical Chemists (IFCC) units (mmol/mol) on the right-hand axis, or vice versa, if feasible. Even when displaying results other than glucose or HbA1c, authors are encouraged to display graphs with tic-marks and (optionally) labels on the right-hand axis of the graph as well as on the customary left-hand axis of the graph in order to reduce parallax for the reader.
Correspondence Address
Following the references, provide the name and complete affiliation and institutional email address of the person to whom correspondence should be sent.
Manuscript Revisions
To upload a revision of a manuscript, the submitting author should log in to their Author Center and click on “Revised Manuscripts in Draft.” All revised submissions will be required to meet all formatting conditions described herein. Submissions that do not satisfy these requirements will be un-submitted and returned to the submitting author for proper configuration.
Letters to the Editor
Diabetes Technology & Therapeutics will consider Letters to the Editor commenting on the scientific content of an article published in the Journal. Letters should not exceed 500 words of text and 5 references. Letters submitted for publication must be original and must not be submitted to any other publication simultaneously.
Patient Release Information
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The submitting author should provide written confirmation of this critical information. Acceptable forms of consent statements are emails or letters. The Journal does not provide a generic patient release form.
The written consent must contain specific information about the patient's name, age, and if pertinent, conservatorship – as well as stated permission – granting the Journal the rights to publish the photograph within its pages (which includes the name of the Journal and article title).
For questions regarding manuscript submissions, contact our Author Services Division.
